Best savings interest rates today, July 17, 2025 (top account pays 4.3% APY)
Banks with the best savings interest rates today
Savings account rates have been trending down since last year, when the Federal Reserve began cutting the federal funds rate.
The good news is that many high-yield savings accounts still offer rates of around 4% APY and up. The best rates are typically offered by online banks, although you may be able to find comparable savings interest rates at some credit unions and community banks.
As of July 17, 2025, the highest savings account rate available from our partners is 4.3% APY. This rate is offered by EverBank and Openbank and requires no minimum opening deposit.
Here is a look at some of the best savings interest rates available today from our verified partners:
How do I choose the best savings account?
Selecting a savings account with a competitive interest rate is important. The higher the rate, the faster your balance will grow over time. That said, the interest rate shouldn't be your only point of comparison.
Other factors, such as fees, ATM locations, the bank's reputation, and more should also be considered. The best savings accounts offer a combination of high rates, low fees, accessibility, and an overall positive banking experience.
Not sure where to start? Check out our ranking of the 10 best high-yield savings accounts available today.
Savings account interest rate forecast
Following several years of near-zero interest rates, the Federal Reserve began raising the the federal funds rate in 2022 in order to combat rapidly rising inflation. As a result, savings interest rates skyrocketed, reaching a 15-year high.
However, in late 2024, the Fed implemented a series of cuts to the federal funds rate, and savings account rates have started dropping. It's also expected that the Fed will implement more rate cuts in 2025.
It's difficult to predict exactly how and when interest rates will change going forward, but one thing is for sure: Today's high savings account rates won't last forever. So, if you're hoping to give your savings a boost and take advantage of the best rates on the market, there's no better time than now.
How to open a savings account
The requirements involved in opening a savings account vary by financial institution. However, if you're ready to open an account, you can follow these general steps:
Research savings account rates: Of course, when choosing a savings account, one of the most important factors to evaluate are the interest rates. Be sure that you select a savings account with a competitive rate to help your money grow.
Figure out your must-haves: Although savings account interest rates should be top of mind, that's not the only factor to consider. You'll also want to think about what else you need from your account, whether it's no minimum balance requirement, low fees, or other perks. Finding a savings account with a solid rate that also helps you achieve your goals is key.
Prepare documentation: Opening a bank account requires you to provide a few important personal details and documents. Before you start your application, be sure you have your Social Security number, driver's license or passport number, and proof of address.
Fill out the application: In many cases, you can apply for savings account online. However, some financial institutions may require you to visit the branch in person to apply. Either way, the application for a new savings account should only take a few minutes to complete. In many cases, you'll get your approval decision instantly.
Fund your account: Once your savings account application is approved, you'll need to add funds to the account. Be sure you're aware of any minimum opening deposit requirements and timeline for funding.
Read more: Step-by-step instructions for opening a high-yield savings account
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
11 minutes ago
- Wall Street Journal
Stock Market Today: Dow Futures Waver; Earnings, Powell in Spotlight — Live Updates
More big-name earnings are on the slate Tuesday, and will jostle for investors' attention with global tariff negotiations and the Federal Reserve chair's last scheduled remarks before the bank's next rate-setting meeting. Quarterly results are due this morning from blue chips including Coca-Cola, General Motors and Lockheed Martin. This week, over S&P 500 100 companies are reporting, with Alphabet and Tesla kicking off results for the Magnificent Seven. Powell will speak at a conference Tuesday in Washington, D.C. at 8:30 a.m. ET. Stock futures were muted early Tuesday. Largely upbeat earnings have helped indexes squeeze out more record highs in recent days, including on Monday. In recent trading: S&P 500 and Nasdaq-100 futures edged higher. Contracts for the Dow industrials wavered. Treasury yields inched up. The 10-year yield stood at around 4.39%. The WSJ Dollar Index strengthened modestly. 📧 Get smarter about markets with our free weekday morning and evening newsletters.
Yahoo
29 minutes ago
- Yahoo
AstraZeneca pledges $50bn US investment ahead of drugs tariffs
British pharmaceuticals giant AstraZeneca has revealed it plans to invest $50 billion (£37 billion) in America over the next five years. The commitment came only a week ahead of expected confirmation from Donald Trump of swingeing tariffs of up to 200% on imported drugs The investment will be made in medicines manufacturing and R&D, and create tens of thousands of high skilled jobs, the Cambridge based company said. By 2030 half the company's expected $80 billion of revenues will be generated in the USA. The investments will include a new multi-billion dollar drug substance manufacturing centre focused on chronic diseases in Virginia. It will be the company's biggest commitment to a single facility anywhere in the world. It will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The $50 billion investment also includes: Expansion of an R&D facility in Gaithersburg, Maryland; an R&D centre in Kendall Square, Cambridge, Massachusetts; manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; and specialty manufacturing expansion in Coppell, Texas Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here." Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. 'This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. 'Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth." Pascal Soriot, CEO, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally." The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. The company employs more than 18,000 people and support 92,000 jobs across the United States. The US represents 42% of total revenue. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Universal Music Group confidentially files for US stock market listing
Universal Music Group (UMG) has submitted a confidential application with the Securities and Exchange Commission (SEC) to sell its shares in the US. The firm will not receive any proceeds from the sale, UMG said in a statement on Tuesday. 'The number of ordinary shares to be offered and the price range for the proposed offering have not yet been determined,' it added. The listing also remains subject to review by the SEC. The world's biggest music company, which represents artists like Taylor Swift, Billie Eilish, and Lady Gaga, is already listed in Amsterdam and has a stock market valuation there of almost €50 billion. The firm is both American and Dutch, holding its corporate headquarters in Hilversum, the Netherlands, and its operational headquarters in Santa Monica in the US state of California. Related World's biggest music labels sue AI song-generators for copyright infringement Universal Music Group and Spotify sign new deal as Björk slams streaming company UMG said in January that it would plan for the US listing after pressure from major hedge fund investor Pershing Square. Billionaire Bill Ackman, who leads Pershing Square, argued that a listing in the US would substantially boost UMG's value. Despite a dip caused by Trump's tariffs, US stock markets are now enjoying a rebound with the Nasdaq and the S&P 500 closing at record highs on Monday. The S&P 500 rose 0.1% and edged past its all-time high set last Thursday, the Nasdaq composite added 0.4% to its own record, while the Dow Jones Industrial Average dropped by less than 0.1%. Error while retrieving data Sign in to access your portfolio Error while retrieving data
